Trial Profile
Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of Waldenstrom's Macroglobulinaemia (WM): a Randomized Phase II Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms R2W
- 17 Jun 2021 Status changed to completed.
- 05 Sep 2020 Status changed from active, no longer recruiting to discontinued.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology